Page 46 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $12.03
52wk Low $8.21 Theravance Biopharma, Inc. TBPH $9.79
901 Gateway Boulevard
South San Francisco, CA 94080

(USD - in millions) www.theravance.com
Market Cap 466.7
Enterprise 413.4
Basic Shares Out. 48.56 COMPANY OVERVIEW
Float 16.00
Institutional Holdings 50.09% Detailed Analysis:Channelchek.com
Short Interest 7.52
Avg. 90-Day Volume 0.36 Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a
Difference® in people's lives. In pursuit of its purpose, the Company
leverages decades of expertise, which has led to the development of
FDA-approved YUPELRI® (revefenacin) inhalation solution indicated
EPS Data for the maintenance treatment of patients with chronic obstructive
pulmonary disease (COPD). Ampreloxetine, its late-stage
2021 2022 2023 investigational norepinephrine reuptake inhibitor in development for
CQ1 (1.24) (0.34) (0.35) symptomatic neurogenic orthostatic hypotension, has the potential to
CQ2 (0.80) (0.11) (0.28) be a first in class therapy effective in treating a constellation of cardinal
symptoms in multiple system atrophy patients. The Company is
CQ3 (0.48) 12.14 (0.17) committed to creating/driving shareholder value.
CQ4 (0.43) (0.15) (0.17)
CY (2.87) 11.85 (1.00) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 4.43
ROE (ttm) -16.86
Debt-to-Total Cap. (mrq) 18.75
Fiscal Year End 31-Dec
901 Gateway BSouth San FraCA 94080

Key Executives
CEO: Winningham, Rick
CFO: Sawaf, Aziz
COO: N/A
IR: Cohen, Gail
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures